comprehensive -WSS

comprehensive

author：focus 2025-10-01 00:16:47 - browse：2

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： In search for therapies for solid tumors, companies turn to claudin

hotspot

WSS

When a patient nears the end, a feared therapy can comfort

Stanford president’s abrupt resignation sparks debate

Mystery swirls around US soldier who entered North Korea days ago, officials say

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Why getting cancer drugs just got harder for rural patients

Obesity now affects over 1 billion people worldwide, study finds

leisure time

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A new ‘biological computer' targets cancer while sparing healthy cells

Activists slam private health insurers over coverage restrictions

Mystery swirls around US soldier who entered North Korea days ago, officials say

Alkermes shareholders re

Mystery swirls around US soldier who entered North Korea days ago, officials say

The high cost of giving birth even with insurance

Hormonal contraceptives don’t actually treat endometriosis

Psychedelics group wrestles with new pharma identity

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

leisure time

When a patient nears the end, a feared therapy can comfort

Sanders wants to replace patents with prizes for drug inventions

Are infertility treatments 'essential' during the Covid

Dementia risk linked to living in disadvantaged areas: Study

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

International team creates first chimeric human

explore

hotspot

focus

hotspot